Baseline demographics and disease severity characteristics
| Characteristic* | Placebo,n = 162† | Adalimumab 40 mg eow, n = 151† |
|---|---|---|
| DLQI, Dermatology Life Quality Index; eow, every other week; FACIT-Fatigue, Functional Assessment of Chronic Illness Therapy—Fatigue Scale; HAQ DI, Health Assessment Questionnaire Disability Index; MCS, mental component summary; PASI, Psoriasis Area and Severity Index; PCS, physical component summary; SF-36, Short-Form 36 Health Survey; VAS, visual analogue scale. | ||
| *Values are mean (SD) unless specified. | ||
| p = NS for comparisons between-treatment groups for all baseline characteristics. | ||
| †n = 162 for placebo, n = 151 for adalimumab except where specifically noted. | ||
| ‡In patients with at least 3% body surface area psoriasis involvement. | ||
| Age, years | 49.2 (11.1) | 48.6 (12.5) |
| Sex, male | 54.9% | 56.3% |
| Race, white | 93.8% | 97.4% |
| Psoriatic arthritis duration, years | 9.2 (8.7) | 9.8 (8.3) |
| Psoriasis duration, years | 17.1 (12.6) | 17.2 (12.0) |
| C reactive protein, mg/dl (normal <0.287) | 1.4 (1.7) | 1.4 (2.1) |
| Patients taking methotrexate at baseline | 50% | 51% |
| Tender joint count (0–78 joints) | 25.8 (18.0) | 23.9 (17.3) |
| Swollen joint count (0–76 joints) | 14.3 (11.1) | 14.3 (12.2) |
| HAQ DI (range 0–3) | 1.0 (0.7) | 1.0 (0.6) |
| SF-36 PCS score | 33.3 (9.8) | 33.2 (9.9), n = 148 |
| SF-36 MCS score | 46.6 (12.2) | 48.1 (10.2), n = 148 |
| FACIT-Fatigue (range 0–52) | 30.8 (12.2), n = 161 | 30.8 (12.1), n = 150 |
| Patient’s assessment of pain(0–100 mm VAS) | 48.8 (21.7), n = 161 | 51.1 (21.4) |
| Patient’s global assessment of disease activity(0–100 mm VAS) | 48.1 (21.2), n = 161 | 47.1 (23.2) |
| PASI (range 0–72)‡ | 8.3 (7.3), n = 69 | 7.4 (6.1), n = 69 |
| DLQI (range 0–30)‡ | 10.3 (7.5), n = 68 | 8.6 (6.6), n = 66 |
| Physician’s global assessment of psoriasis,% “clear” or “almost clear”‡ | 1.4%, n = 70 | 1.4%, n = 70 |